LCTX (Lineage Cell Therapeutics) Research & Development: $18.85 Mil (TTM As of Mar. 2026)


LCTX Lineage Cell Therapeutics Inc LCTX
78 GF Score
Price $1.26
GF Value $1.33
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Lineage Cell Therapeutics Research & Development?

Lineage Cell Therapeutics LCTX +0.80% 78 Research & Development is $18.85 Mil as of Mar. 2026. GuruFocus rates LCTX with a GF Score™ of 78/100 and a GF Value™ of $1.33 (Fairly Valued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Lineage Cell Therapeutics's Research & Development for the three months ended in Mar. 2026 was $4.23 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $18.85 Mil.

Lineage Cell Therapeutics  (AMEX:LCTX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Lineage Cell Therapeutics Research & Development Related Terms

Lineage Cell Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Lineage Cell Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lineage Cell Therapeutics Research & Development Chart

Lineage Cell Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.91 13.99 15.71 12.47 17.73

Lineage Cell Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.11 3.11 3.27 8.24 4.23
LCTX
78GF Score
Lineage Cell Therapeutics Inc LCTX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lineage Cell Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $18.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $18.85 Mil mean?
Lineage Cell Therapeutics (LCTX) has a Research & Development of $18.85 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Lineage Cell Therapeutics and its competitors.
Is Lineage Cell Therapeutics' Research & Development too high?
Lineage Cell Therapeutics' current Research & Development is $18.85 Mil. Overall, Lineage Cell Therapeutics has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lineage Cell Therapeutics' Research & Development compare to FATE and ABEO?
Lineage Cell Therapeutics' Research & Development of $18.85 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Lineage Cell Therapeutics and its competitors. Lineage Cell Therapeutics's current Research & Development is $18.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lineage Cell Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Lineage Cell Therapeutics (LCTX) is currently considered Fairly Valued. The stock's GF Value™ is $1.33, compared to a current price of $1.26 — trading 5.3% below its estimated fair value. The current Research & Development is $18.85 Mil. Lineage Cell Therapeutics' overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Lineage Cell Therapeutics (LCTX), the current Research & Development is $18.85 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lineage Cell Therapeutics (LCTX) Overvalued in 2026?

Based on GuruFocus' analysis, Lineage Cell Therapeutics stock appears to be undervalued. The current stock price of $1.26 is trading 5.3% below its estimated GF Value™ of $1.33. GuruFocus considers Lineage Cell Therapeutics to be Fairly Valued.

Key valuation signals for LCTX:

  • Research & Development: $18.85 Mil
  • GF Value™: $1.33 vs. price of $1.26 (5.3% below fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the LCTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lineage Cell Therapeutics Business Description

Other Exchanges LCTX:IsraelBT3:Germany
Address 2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
78GF Score

Get the complete analysis for LCTX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.26
Price
$1.33
GF Value